
UNIVERSITY



# A new in vitro model of the healthy human ileum and its associated microbiota







MED#S

Auriane Bron<sup>1,2,3</sup>, Chloé Beltramo<sup>1,2,3</sup>, Sylvain Denis<sup>1,3</sup>, Claude Durif<sup>1,3</sup>, Yolanda F. Otero<sup>4</sup>, Charlotte Deschamps<sup>1,3</sup>, Tom Van de Wiele<sup>2,3</sup>, Stéphanie Blanquet-Diot<sup>1,3</sup>



<sup>1</sup>Université Clermont Auvergne, UMR 454 MEDIS UCA-INRAE, Microbiology, Digestive Environment and Health, Clermont-Ferrand, France <sup>2</sup> Center for Microbial Ecology and Technology (CMET), Department of Biotechnology, Ghent University, Ghent, Belgium; <sup>3</sup>International associated laboratory host microbes interactions in the human gut (HOMIGUT); <sup>4</sup> Valbiotis R&D Riom Center, Riom, France.



g\_Paraclostridium

Phocaeicola g Ruminococcus

g\_\_Terrisporobacter

Others


## INTRODUCTION

The human small intestine is the main site of food digestion and nutrient absorption. Its microbiota certainly plays a key role in host health, but until now it was largely understudied due to sampling invasiveness, especially in healthy volunteers.

Up to now, there is no available in vitro system simulating the ileal compartment and its associated microbiota, that has been fully developed and validated based on in vivo data in humans.


Aim of this study: Development of an in vitro dynamic model of the healthy human ileum microbiota, reproducing both luminal and mucosal microenvironments.

# MATERIAL & METHODS



# RESULTS

## Microbiota activity



### Gas composition


- Gas production stabilized at day 4 (D4) in M-ARILE and at day 2 (D2) in M-ARCOL.
- $CO_2$ Variations in percentages between S1 & S2, only in M-ARILE and for all donors.
- No methane production in M-ARILE but CH<sub>4</sub> measured in M-ARCOL for donor F1.

## **SCFA** concentrations


. Lower total SCFA, acetate, propionate and butyrate concentrations in M-ARILE versus M-ARCOL for most of the donors.

. No butyrate production for donor F1 in M-ARILE.

Donor M1




Kruskal-Wallis test on mean stabilized SCFA production (D6 to D10) ±SEM with Dunn's multiple comparisons test (n=3). ns: not significant; \*p<0.05; \*\*p<0.01; \*\*\*p<0.001; \*\*\*\*p<0.0001



M-ARILE for all donors. In M-ARILE, SCFA proportions are donor dependant, but not in M-ARCOL.


(Inoc: inoculum)


#### RESULTS Microbiota composition



- . Lower bacterial load in the luminal compartment from M-ARILE compared to M-ARCOL.
- . In the mucosal part, no difference between the two models, whatever the donor.


#### **β-diversity** RDA analysis of environment with Bray-Curtis method without donor effect






. Stabilization of bacterial profiles at day 6 in the luminal compartments of both models and, at day 8-10 in the mucosal phase.

Higher abundances of Clostridium, Escherichia and Enterococcus genera in M-ARILE versus M-ARCOL.




- . Significant differences in lumen and mucus-associated microbiota, far more pronunced between the stool inoculum and the M-ARILE than the M-ARCOL.
- . Differential clustering of ileal and colonic samples in both the luminal and the mucosal compartments.

#### $\alpha$ -diversity



Consistency between metabarcoding analysis and methane production (only in M-ARCOL for donor F1).



. Similar  $\alpha$ -diversity between M-ARILE and M-ARCOL (D6 to D10).

## **VALIDATION**

Validation of M-ARILE regarding microbiota activity and composition				M-ARILE <i>versus</i> M-ARCOL	<i>In vivo-in vitro</i> correlation
	Microbiota activity	SCFA production <sup>I, II</sup>	Total SCFA	K	✓
			Acetate	K	✓
			Propionate	Z	✓
			Butyrate	Z	✓
	Microbiota load	Total bacteria <sup>III, IV</sup>	Luminal	K	✓
			Mucosal	*	X
	Microbiota composition <sup>III, V</sup> (Genera)	Bacteroides	Luminal & Mucosal	Z	✓
		Clostridium		7	✓
		Escherichia		7	✓
		Enterococcus		7	<b>✓</b>
		Ruminococcus		٦	<b>✓</b>

<sup>I</sup>Cummings et al., 1987; <sup>II</sup>Zoetendal et al., 2012; <sup>III</sup>Delbaere et al., 2022; <sup>IV</sup>Deschamps et al., 2020; <sup>V</sup>Martinez-Guryn et al., 2019

# DISCUSSION



Most of the results in M-ARILE and M-ARCOL are in accordance with in vivo data in healthy human.



Metabolomic analysis are on going to better describe ileal and colonic *in vitro* samples

The M-ARILE model will provide a powerful platform for mechanistic studies on healthy human ileal microbiome and its interaction with nutrient, drug or enteric pathogen found in the small intestine.

